摘要
目的中日合作对河南省结核菌二线药物的耐药疫情进行调查研究.方法从2004年9月1日～2005年5月31日,由日本厚生省提供研究经费,按照世界卫生组织标准方案,在河南省胸科医院等地市医院,连续收选220例涂阳结核患者,进行结核菌一线和二线药物药敏试验.结果一线药物显示初始耐药者和获得性耐药者任一耐药率均依链霉素(SM)、异烟肼(INH)、利福平(RFP)、乙胺丁醇(EMB)的顺序递减,而二线药物却情况不同,初治患者的氧氟杀星(OFLX)和阿米卡星(AMK)的耐药率已经高达12.8%和7.4%,说明这两种药被广泛用于一般细菌抗感染治疗,形成了很高的初始耐药率.耐多药(MDR)患者的二线药药物选择却很不容乐观.比如OFLX+AMK两个主要的耐药率已经达到48.1%.而其他一些组合的耐药率也超过了40%.结论河南省结核菌二线药物的耐药疫情处于一个较高水平.以氧氟杀星和阿米卡星为主药的二线治疗方案,需要及时调整.
Objective To determine second line tuberculosis drug resistance prevalence in Henan China. Methods From 1 September 2004 to 31 May 2005,Supported by Ministry of Health and Welfare of Japan. According to WHO standard guideline, 220 tuberculosis cases were enrolled in this project in Henan Chest hospital and other hospitals. All tuberculosis cases have been examined first line and second line drug sensitivity tests. Results First line drugs, decrease in order of SM, INH,RFP,EMB. But second line drug resistance is quite different. Initial drug resistance rate of OFLX and AMK is 12.8% and 7.4%. It reflected that these two drugs have been often used for common bacteria infection and lead to a serious high drug resistance rate. Among MDR -TB patients, selection of treatment regimen is also uneasy. OFLX and AMK drug resistance rate is 48. 1%. Other combined regimen is more than 40%. Conclusion Second line drug resistance prevalence is very serious in Henan. Including OFLX and AMK second line treatment regimen need modification as soon as possible.
出处
《医药论坛杂志》
2005年第19期14-16,共3页
Journal of Medical Forum
基金
日本厚生省提供基金资助
关键词
结核
耐药
二线药物
Tuberculosis
Drug Resistance
Second line Drug
